Checks whether low antibody levels contribute to fatigue in multiple sclerosis
Observes adults with multiple sclerosis, testing antibody levels to study fatigue.
Plain-language title generated from the registry record
Registry title: Immunoglobulin Deficiency a Treatable Cause of Fatigue in Patients With Multiple Sclerosis (MS)?
Key facts
- Where
- Bern, SwitzerlandSee the site
Could this be for you?
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 18 and 65 years old?
Source: NCT05357781, who can take part
Where in Switzerland
- University Hospital of Bern (Inselspital)Bern, SwitzerlandTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Insel Gruppe AG, University Hospital Bern
- Trial code
- NCT05357781
- Record updated
- 1 May 2026
- Original description
The investigators hypothesize that hypogammaglobulinemia (defined as IgG serum concentration <7.0g/L) is a treatable cause of fatigue in people with MS:Read full original descriptionShow less
Immunoglobulin Deficiency a Treatable Cause of Fatigue in Patients With Multiple Sclerosis (MS)? - A Prospective Observational Fatigue Trial
The investigators hypothesize that hypogammaglobulinemia (defined as IgG serum concentration <7.0g/L) is a treatable cause of fatigue in people with MS:
The primary objective is to prove the link between hypogammaglobulinemia and fatigue in patients with multiple sclerosis.
The secondary objective is to show that fatigue is mediated via frequent infections in people with MS and hypogammaglobulinemia.
Inclusion: Diagnosis of Multiple Sclerosis following McDonald 2017-Criteria; Age 18-65 years; Stable MS disease at inclusion (definition: no clinical relapse, no MRI activity, stable disability within the last 12 months); Unchanged immunotherapy within the last 12 months; Expanded Disability Status Scale (EDSS) level <4 points indicating fully ambulatory patients; Capability of written informed consent.
Exclusion: Immunglobulin replacement therapy or indication for immunoglobulin replacement therapy; Severe depression (definition: Beck Depression Index-II (BDI-II) ≥29 points) or other established psychiatric diagnosis; Fatigue aggravating factors such: liver/renal/thyroid dysfunction, substance abuse, medication (tranquilizers /antiepileptics/psychopharmaceuticals), chronic infectious disease (like hepatitis/HIV); Other neurodegenerative/autoimmune disease; Immunodeficiency other than hypogammaglobulinemia; Severe Sleepiness (definition: Epworth-Sleepiness-Scale (ESS) >16 points); Patients not able to give written consent; Vulnerable patients such as children, pregnant women and prisoners.